Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager

Moberg Pharma AB (publ)

STO:MOB

Watchlist

Dividends

Price: 11.97 SEK -5.52%

Market Cap: 558.9m SEK

Have any thoughts about
Moberg Pharma AB (publ)?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Fubotv Inc NYSE:FUBO	Media
US	Bank of America Corp NYSE:BAC	Banking
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Uber Technologies Inc NYSE:UBER	Road & Rail
CN	NIO Inc NYSE:NIO	Automobiles
US	Fluor Corp NYSE:FLR	Construction
US	Jacobs Engineering Group Inc NYSE:J	Professional Services
US	TopBuild Corp NYSE:BLD	Consumer products
US	Abbott Laboratories NYSE:ABT	Health Care
US	Chevron Corp NYSE:CVX	Energy
US	Occidental Petroleum Corp NYSE:OXY	Energy
US	Matrix Service Co NASDAQ:MTRX	Construction
US	Automatic Data Processing Inc NASDAQ:ADP	Technology
US	Qualcomm Inc NASDAQ:QCOM	Semiconductors
US	PayPal Holdings Inc NASDAQ:PYPL	Technology
US	Ambarella Inc NASDAQ:AMBA	Semiconductors

Add Price Alert

Price Target:

Last Price: 11.97 SEK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

MOB Alert

Moberg Pharma AB (publ)

11.97

-0.70 (-5.52%)

52 Week Range	7.05 38.92
Price Target

We'll email you a reminder when the closing price reaches SEK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Fubotv Inc NYSE:FUBO	US
	Bank of America Corp NYSE:BAC	US
	Palantir Technologies Inc NYSE:PLTR	US
	Uber Technologies Inc NYSE:UBER	US
	NIO Inc NYSE:NIO	CN
	Fluor Corp NYSE:FLR	US
	Jacobs Engineering Group Inc NYSE:J	US
	TopBuild Corp NYSE:BLD	US
	Abbott Laboratories NYSE:ABT	US
	Chevron Corp NYSE:CVX	US
	Occidental Petroleum Corp NYSE:OXY	US
	Matrix Service Co NASDAQ:MTRX	US
	Automatic Data Processing Inc NASDAQ:ADP	US
	Qualcomm Inc NASDAQ:QCOM	US
	PayPal Holdings Inc NASDAQ:PYPL	US
	Ambarella Inc NASDAQ:AMBA	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Moberg Pharma AB (publ)

What unique competitive advantages
does Moberg Pharma AB (publ) hold over its rivals?

What risks and challenges
does Moberg Pharma AB (publ) face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Moberg Pharma AB (publ).

What unique competitive advantages
does Moberg Pharma AB (publ) hold over its rivals?

What risks and challenges
does Moberg Pharma AB (publ) face in the near future?

Has there been any significant insider trading activity
in Moberg Pharma AB (publ) recently?

Summarize the latest earnings call
of Moberg Pharma AB (publ).

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Moberg Pharma AB (publ).

Provide P/S
for Moberg Pharma AB (publ).

Provide P/E
for Moberg Pharma AB (publ).

Provide P/OCF
for Moberg Pharma AB (publ).

Provide P/FCFE
for Moberg Pharma AB (publ).

Provide P/B
for Moberg Pharma AB (publ).

Provide EV/S
for Moberg Pharma AB (publ).

Provide EV/GP
for Moberg Pharma AB (publ).

Provide EV/EBITDA
for Moberg Pharma AB (publ).

Provide EV/EBIT
for Moberg Pharma AB (publ).

Provide EV/OCF
for Moberg Pharma AB (publ).

Provide EV/FCFF
for Moberg Pharma AB (publ).

Provide EV/IC
for Moberg Pharma AB (publ).

Show me price targets
for Moberg Pharma AB (publ) made by professional analysts.

What are the Revenue projections
for Moberg Pharma AB (publ)?

How accurate were the past Revenue estimates
for Moberg Pharma AB (publ)?

What are the Net Income projections
for Moberg Pharma AB (publ)?

How accurate were the past Net Income estimates
for Moberg Pharma AB (publ)?

What are the EPS projections
for Moberg Pharma AB (publ)?

How accurate were the past EPS estimates
for Moberg Pharma AB (publ)?

What are the EBIT projections
for Moberg Pharma AB (publ)?

How accurate were the past EBIT estimates
for Moberg Pharma AB (publ)?

Compare the revenue forecasts
for Moberg Pharma AB (publ) with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Moberg Pharma AB (publ) and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Moberg Pharma AB (publ) against its competitors.

Analyze the profit margins
(gross, operating, and net) of Moberg Pharma AB (publ) compared to its peers.

Compare the P/E ratios
of Moberg Pharma AB (publ) against its peers.

Discuss the investment returns and shareholder value creation
comparing Moberg Pharma AB (publ) with its peers.

Analyze the financial leverage
of Moberg Pharma AB (publ) compared to its main competitors.

Show all profitability ratios
for Moberg Pharma AB (publ).

Provide ROE
for Moberg Pharma AB (publ).

Provide ROA
for Moberg Pharma AB (publ).

Provide ROIC
for Moberg Pharma AB (publ).

Provide ROCE
for Moberg Pharma AB (publ).

Provide Gross Margin
for Moberg Pharma AB (publ).

Provide Operating Margin
for Moberg Pharma AB (publ).

Provide Net Margin
for Moberg Pharma AB (publ).

Provide FCF Margin
for Moberg Pharma AB (publ).

Show all solvency ratios
for Moberg Pharma AB (publ).

Provide D/E Ratio
for Moberg Pharma AB (publ).

Provide D/A Ratio
for Moberg Pharma AB (publ).

Provide Interest Coverage Ratio
for Moberg Pharma AB (publ).

Provide Altman Z-Score Ratio
for Moberg Pharma AB (publ).

Provide Quick Ratio
for Moberg Pharma AB (publ).

Provide Current Ratio
for Moberg Pharma AB (publ).

Provide Cash Ratio
for Moberg Pharma AB (publ).

What is the historical Revenue growth
over the last 5 years for Moberg Pharma AB (publ)?

What is the historical Net Income growth
over the last 5 years for Moberg Pharma AB (publ)?

What is the current Free Cash Flow
of Moberg Pharma AB (publ)?

Discuss the annual earnings per share (EPS)
trend over the past five years for Moberg Pharma AB (publ).

MOB

Balance Sheet

Total Current Liabilities

Moberg Pharma AB (publ)
Total Current Liabilities

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

Adjust for Inflation

Moberg Pharma AB (publ)
Total Current Liabilities Peer Comparison

Comparables:

CALTX

CAMX

SECARE

IRLAB A

FLERIE

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company		Total Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Moberg Pharma AB (publ) STO:MOB	Total Current Liabilities kr20.5m	CAGR 3-Years -36%	CAGR 5-Years N/A	CAGR 10-Years N/A
	Calliditas Therapeutics AB STO:CALTX	Total Current Liabilities kr429.8m	CAGR 3-Years 52%	CAGR 5-Years 59%	CAGR 10-Years N/A
	Camurus AB STO:CAMX	Total Current Liabilities kr428.8m	CAGR 3-Years 27%	CAGR 5-Years 29%	CAGR 10-Years N/A
S	Swedencare AB (publ) STO:SECARE	Total Current Liabilities kr357.1m	CAGR 3-Years 61%	CAGR 5-Years 77%	CAGR 10-Years N/A
	IRLAB Therapeutics AB STO:IRLAB A	Total Current Liabilities kr36.7m	CAGR 3-Years 21%	CAGR 5-Years 24%	CAGR 10-Years N/A
I	InDex Pharmaceuticals Holding AB STO:FLERIE	Total Current Liabilities kr31.6m	CAGR 3-Years 31%	CAGR 5-Years 7%	CAGR 10-Years N/A

What is Moberg Pharma AB (publ)'s Total Current Liabilities?

Total Current Liabilities
20.5m SEK

Based on the financial report for Dec 31, 2023, Moberg Pharma AB (publ)'s Total Current Liabilities amounts to 20.5m SEK.

What is Moberg Pharma AB (publ)'s Total Current Liabilities growth rate?

Total Current Liabilities CAGR 3Y
-36%

Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for Moberg Pharma AB (publ) have been -36% over the past three years .

Moberg Pharma AB (publ)
STO:MOB

Moberg Pharma AB (publ)
Total Current Liabilities

Moberg Pharma AB (publ)
Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

See Also

What is Moberg Pharma AB (publ)'s Total Current Liabilities?

Total Current Liabilities
20.5m SEK

What is Moberg Pharma AB (publ)'s Total Current Liabilities growth rate?

Total Current Liabilities CAGR 3Y
-36%

Company

Help

Tools

Stocks

Moberg Pharma AB (publ) STO:MOB

Moberg Pharma AB (publ) Total Current Liabilities

Moberg Pharma AB (publ) Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis Latest Figures & CAGR of Competitors

See Also

What is Moberg Pharma AB (publ)'s Total Current Liabilities? Total Current Liabilities 20.5m SEK

What is Moberg Pharma AB (publ)'s Total Current Liabilities growth rate? Total Current Liabilities CAGR 3Y -36%

Company

Help

Tools

Stocks

Moberg Pharma AB (publ)
STO:MOB

Moberg Pharma AB (publ)
Total Current Liabilities

Moberg Pharma AB (publ)
Total Current Liabilities Peer Comparison

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

What is Moberg Pharma AB (publ)'s Total Current Liabilities?

Total Current Liabilities
20.5m SEK

What is Moberg Pharma AB (publ)'s Total Current Liabilities growth rate?

Total Current Liabilities CAGR 3Y
-36%